{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:37:09Z","timestamp":1791844629492,"version":"4.3.4"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2018.4080","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T18:03:56Z","timestamp":1541527436000},"page":"e184080","source":"Crossref","is-referenced-by-count":27,"title":["Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials"],"prefix":"10.1001","volume":"1","author":[{"given":"Richard E.","family":"Kennedy","sequence":"first","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary R.","family":"Cutter","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie E.","family":"Fowler","sequence":"additional","affiliation":[{"name":"University of Alabama at Birmingham, Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lon S.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"issue":"1","key":"zoi180182r1","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/archneurol.2010.343","article-title":"Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer\u2019s Disease Neuroimaging Initiative.","volume":"68","author":"Schneider","year":"2011","journal-title":"Arch Neurol"},{"issue":"3","key":"zoi180182r2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","article-title":"Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization.","volume":"74","author":"Petersen","year":"2010","journal-title":"Neurology"},{"key":"zoi180182r3","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment scale that broaden its scope: the Alzheimer\u2019s Disease Cooperative Study.","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"11","key":"zoi180182r4","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR): current version and scoring rules.","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"3","key":"zoi180182r5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d: a practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"3","key":"zoi180182r6","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jalz.2013.03.003","article-title":"Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer\u2019s disease.","volume":"10","author":"Kennedy","year":"2014","journal-title":"Alzheimers Dement"},{"key":"zoi180182r7","first-page":"6","article-title":"Development of the Alzheimer\u2019s Disease Cooperative Study.","volume":"1","author":"Thal","year":"1997","journal-title":"Int J Geriatr Psychopharmacol"},{"issue":"7","key":"zoi180182r8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease.","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"issue":"5","key":"zoi180182r9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jalz.2009.07.038","article-title":"Current Alzheimer\u2019s disease clinical trials: methods and placebo outcomes.","volume":"5","author":"Schneider","year":"2009","journal-title":"Alzheimers Dement"},{"issue":"17","key":"zoi180182r10","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease: the Alzheimer\u2019s Disease Cooperative Study.","volume":"336","author":"Sano","year":"1997","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi180182r11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer\u2019s disease: Alzheimer\u2019s Disease Cooperative Study.","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"issue":"8","key":"zoi180182r12","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jama.283.8.1007","article-title":"Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer\u2019s Disease Cooperative Study.","volume":"283","author":"Mulnard","year":"2000","journal-title":"JAMA"},{"issue":"21","key":"zoi180182r13","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"issue":"15","key":"zoi180182r14","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","article-title":"High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial.","volume":"300","author":"Aisen","year":"2008","journal-title":"JAMA"},{"issue":"17","key":"zoi180182r15","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial.","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"issue":"16","key":"zoi180182r16","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","article-title":"A phase II trial of huperzine A in mild to moderate Alzheimer disease.","volume":"76","author":"Rafii","year":"2011","journal-title":"Neurology"},{"issue":"6","key":"zoi180182r17","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease.","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"zoi180182r18","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/archgenpsychiatry.2011.72","article-title":"Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease.","volume":"68","author":"Tariot","year":"2011","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"zoi180182r20","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/10543400802609797","article-title":"MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets.","volume":"19","author":"Siddiqui","year":"2009","journal-title":"J Biopharm Stat"},{"issue":"4","key":"zoi180182r21","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1037\/1082-989X.3.4.486","article-title":"Fixed- and random-effects models in meta-analysis.","volume":"3","author":"Hedges","year":"1998","journal-title":"Psychol Methods"},{"key":"zoi180182r22","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"2","key":"zoi180182r23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/evo.2005.59.issue-2","article-title":"The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis.","volume":"59","author":"Rosenberg","year":"2005","journal-title":"Evolution"},{"key":"zoi180182r24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor Package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"1","key":"zoi180182r25","first-page":"CD005593","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease.","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi180182r26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1001\/jama.2017.20373","article-title":"Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease: Three randomized clinical trials.","volume":"319","author":"Atri","year":"2018","journal-title":"JAMA"},{"issue":"4","key":"zoi180182r27","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease.","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi180182r28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-170560","article-title":"Potential of low dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) monotherapy for treatment of mild Alzheimer\u2019s Disease: cohort analysis as modified primary outcome in a phase iii clinical trial.","volume":"61","author":"Wilcock","year":"2018","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"zoi180182r29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4.","volume":"67","author":"Bates","year":"2015","journal-title":"J Stat Softw"},{"key":"zoi180182r19","doi-asserted-by":"crossref","DOI":"10.1002\/0470023589","volume-title":"Applied Mixed Models in Medicine","author":"Brown","year":"2006","edition":"2nd ed"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/1\/7\/e184080\/17295038\/kennedy_2018_oi_180182.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T17:26:47Z","timestamp":1550165207000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2018.4080"}},"subtitle":["A Meta-analysis"],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,11,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4080","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]}}}